Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) EBT (2022 - 2025)

Historic EBT for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to -$26.7 million.

  • Zentalis Pharmaceuticals' EBT rose 3357.97% to -$26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.5 million, marking a year-over-year increase of 1650.93%. This contributed to the annual value of -$165.7 million for FY2024, which is 4016.08% up from last year.
  • Zentalis Pharmaceuticals' EBT amounted to -$26.7 million in Q3 2025, which was up 3357.97% from -$26.9 million recorded in Q2 2025.
  • Over the past 5 years, Zentalis Pharmaceuticals' EBT peaked at $10.2 million during Q1 2024, and registered a low of -$99.5 million during Q2 2023.
  • For the 4-year period, Zentalis Pharmaceuticals' EBT averaged around -$51.0 million, with its median value being -$52.3 million (2022).
  • Per our database at Business Quant, Zentalis Pharmaceuticals' EBT soared by 11673.62% in 2024 and then tumbled by 57411.37% in 2025.
  • Quarter analysis of 4 years shows Zentalis Pharmaceuticals' EBT stood at -$48.5 million in 2022, then dropped by 25.87% to -$61.1 million in 2023, then rose by 21.94% to -$47.7 million in 2024, then surged by 44.02% to -$26.7 million in 2025.
  • Its last three reported values are -$26.7 million in Q3 2025, -$26.9 million for Q2 2025, and -$48.3 million during Q1 2025.